Covid drug drives 26% rise in fourth quarter revenue at Gilead

Company said the Covid-19 pandemic continues to affect its sales, but growth expected

The Gilead Sciences headquarters in Foster City, California.
The Gilead Sciences headquarters in Foster City, California.

Gilead Sciences on Thursday forecast its 2021 results above Wall Street estimates after posting a 26 per cent rise in fourth quarter 2020 revenue, driven by sales of its antiviral drug, remdesivir, which is used to treat Covid-19 patients.

Shares of Gilead were up 2.5 per cent in extended trading.

Gilead said the Covid-19 pandemic continues to affect its sales, including its treatments for hepatitis C and HIV, due to fewer people going to their doctors. It expects a gradual recovery in underlying market dynamics starting the second quarter of this year.

Remdesivir, which is sold under the brand name Veklury, brought in $1.9 billion (€1.6bn) in the fourth quarter ended December 31st, above analysts’ estimates of $1.34 billion. Excluding Veklury, Gilead said its quarterly sales fell 7 per cent.

READ MORE

The company said remdesivir continues to be a critical tool during the Covid-19 pandemic, forecasting 2021 sales of up to $3 billion for the drug.

Gilead chief medical officer Merdad Parsey said that unlike current Covid-19 vaccines and some other drugs, remdesivir does not target the spike proteins of the coronavirus, which are altered in some recently-identified, more transmissible variants of the virus.

“We have not so far seen mutations that would impact the efficacy of remdesivir,” he said during a conference call.

Gilead said it continues to work on an inhaled version of the Covid-19 drug – which is given intravenously to hospitalised patients – but more clinical study is required.

For 2021, the California-based company projected an adjusted earnings range with a midpoint of $7.10 per share, on product sales with a midpoint of $24.4 billion, ahead of respective Wall Street estimates of $6.85 per share and $24.27 billion, according to IBES data from Refinitiv.

“We think the $7 number is higher than where investors were looking for and provides a good base to continue to grow,” Jefferies analyst Michael Yee said in an email.

He said Gilead projected 2021 operating expenses at less than analysts have estimated.

The company’s fourth-quarter revenue totalled $7.42 billion, beating the average analyst estimate of $7.33 billion. Adjusted quarterly earnings of $2.19 were ahead of Wall Street expectations of $2.15 per share. – Reuters